| SAL_11082 | Leptin | NA | Standard analysis | Saliva | Metabolic Disorder | Obesity | NA | NA | NA | NA | Homo sapiens | 30605486 | 2019 | P41159 | Protein| SAL_11279 | Alpha-amylase | NA | 2DE, MS, ELISA | Saliva | Metabolic Disorder | Diabetes Mellitus | NA | >1.5 | Upregulated | NA | Homo sapiens | 31174096 | 2019 | B7ZMD7 | Protein| SAL_11280 | Cystatin SA | NA | 2DE, MS, ELISA | Saliva | Metabolic Disorder | Diabetes Mellitus | NA | 8.32 | Upregulated | NA | Homo sapiens | 31174096 | 2019 | P09228 | Protein| SAL_11281 | Immunoglobulin kappa light chain VLJ region | NA | 2DE, MS, ELISA | Saliva | Metabolic Disorder | Diabetes Mellitus | NA | >1.5 | Upregulated | NA | Homo sapiens | 31174096 | 2019 | P0DOX7 | Protein| SAL_11282 | Lactoferrin | NA | 2DE, MS, ELISA | Saliva | Metabolic Disorder | Diabetes Mellitus | NA | >1.5 | Upregulated | NA | Homo sapiens | 31174096 | 2019 | P02788 | Protein| SAL_11283 | Lysozyme precursor | NA | 2DE, MS, ELISA | Saliva | Metabolic Disorder | Diabetes Mellitus | NA | >1.5 | Upregulated | NA | Homo sapiens | 31174096 | 2019 | P61626 | Protein| SAL_11287 | Glycated hemoglobin A | NA | Spectrophotometry | Saliva | Metabolic Disorder | Type II diabetes | NA | NA | Upregulated | NA | Homo sapiens | 31235125 | 2019 | P69905 | Protein| SAL_11988 | Calprotectin | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Obesity | NA | NA | Upregulated | NA | Homo sapiens | 32598403 | 2020 | P05109 | Protein| SAL_11989 | Interleukin-8 | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Obesity | NA | NA | Upregulated | NA | Homo sapiens | 32598403 | 2020 | P10145 | Protein| SAL_11990 | Metalloproteinase-2 | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Obesity | NA | NA | Upregulated | NA | Homo sapiens | 32598403 | 2020 | P08253 | Protein| SAL_11991 | Metalloproteinase-9 | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Obesity | NA | NA | NA | NA | Homo sapiens | 32598403 | 2020 | P14780 | Protein| SAL_11992 | Soluble intercellular adhesion molecule 1 | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Obesity | NA | NA | NA | NA | Homo sapiens | 32598403 | 2020 | Q99930 | Protein| SAL_11993 | Toll like receptor 2 | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Obesity | NA | NA | NA | NA | Homo sapiens | 32598403 | 2020 | O60603 | Protein| SAL_11994 | Tumor necrosis factor-alpha | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Obesity | NA | NA | NA | NA | Homo sapiens | 32598403 | 2020 | P01375 | Protein| SAL_12529 | C-reactive protein | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Type 2 diabetes mellitus | NA | NA | Upregulated | NA | Homo sapiens | 33676486 | 2021 | P02741 | Protein| SAL_12530 | Interleukin-6 | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Type 2 diabetes mellitus | NA | NA | Upregulated | NA | Homo sapiens | 33676486 | 2021 | P05231 | Protein| SAL_12531 | Tumour necrosis factor alpha | Diagnostic | ELISA | Whole Saliva | Metabolic Disorder | Type 2 diabetes mellitus | NA | NA | Upregulated | NA | Homo sapiens | 33676486 | 2021 | P01375 | Protein| SAL_12570 | Albumin (Fragment) | NA | Protein-dye binding | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 9558543 | 1998 | F6KPG5 | Protein| SAL_12571 | Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)] | NA | Quantikine Human EGF Immunoassay | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | 1.20933977 | Upregulated | NA | Homo sapiens | 10989322 | 2000 | P01133 | Protein| SAL_12572 | Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)] | NA | Quantikine Human EGF Immunoassay | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 10989322 | 2000 | P01133 | Protein| SAL_12573 | Serum albumin | NA | colorimetric methods | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | 1.19047619 | Upregulated | NA | Homo sapiens | 11005153 | 2000 | P02768 | Protein| SAL_12574 | Alpha-amylase 1 (EC 3.2.1.1) (1,4-alpha-D-glucan glucanohydrolase 1) (Salivary alpha-amylase) | NA | EPS method | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | 1.1420765 | Upregulated | NA | Homo sapiens | 11005153 | 2000 | P04745 | Protein| SAL_13049 | Beta-hexosaminidase subunit alpha (EC 3.2.1.52) (Beta-N-acetylhexosaminidase subunit alpha) (Hexosaminidase subunit A) (N-acetyl-beta-glucosaminidase subunit alpha) | NA | Chatteriee et al. Method (1975) | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 16700736 | 2006 | P06865 | Protein| SAL_13050 | Beta-hexosaminidase subunit alpha (EC 3.2.1.52) (Beta-N-acetylhexosaminidase subunit alpha) (Hexosaminidase subunit A) (N-acetyl-beta-glucosaminidase subunit alpha) | NA | Chatteriee et al. Method (1975) | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 16700736 | 2006 | P06865 | Protein| SAL_13051 | Beta-hexosaminidase subunit beta (EC 3.2.1.52) (Beta-N-acetylhexosaminidase subunit beta) (Hexosaminidase subunit B) (Cervical cancer proto-oncogene 7 protein) (HCC-7) (N-acetyl-beta-glucosaminidase s | NA | Chatteriee et al. Method (1975) | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 16700736 | 2006 | P07686 | Protein| SAL_13052 | Beta-hexosaminidase subunit beta (EC 3.2.1.52) (Beta-N-acetylhexosaminidase subunit beta) (Hexosaminidase subunit B) (Cervical cancer proto-oncogene 7 protein) (HCC-7) (N-acetyl-beta-glucosaminidase s | NA | Chatteriee et al. Method (1975) | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 16700736 | 2006 | P07686 | Protein| SAL_13053 | Beta-galactosidase (EC 3.2.1.23) (Acid beta-galactosidase) (Lactase) (Elastin receptor 1) | NA | Chatteriee et al. Method (1975) | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 16700736 | 2006 | P16278 | Protein| SAL_13054 | Beta-galactosidase (EC 3.2.1.23) (Acid beta-galactosidase) (Lactase) (Elastin receptor 1) | NA | Chatteriee et al. Method (1975) | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 16700736 | 2006 | P16278 | Protein| SAL_13084 | Alpha-amylase 1 (EC 3.2.1.1) (1,4-alpha-D-glucan glucanohydrolase 1) (Salivary alpha-amylase) | NA | Subjects were asked not to eat, smoke or drink (except water) for an overnight fast prior to collection of saliva samples. Their diets were similar with respect to protein content and uptake of fat and carbohydrates. Socioeconomical status was similar for both groups (survey data). | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | 1.25 | Upregulated | NA | Homo sapiens | 17244479 | 2007 | P04745 | Protein| SAL_13085 | Alpha-amylase 1 (EC 3.2.1.1) (1,4-alpha-D-glucan glucanohydrolase 1) (Salivary alpha-amylase) | NA | Subjects were asked not to eat, smoke or drink (except water) for an overnight fast prior to collection of saliva samples. Their diets were similar with respect to protein content and uptake of fat and carbohydrates. Socioeconomical status was similar for both groups (survey data). | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | 1.2388664 | Upregulated | NA | Homo sapiens | 17244479 | 2007 | P04745 | Protein| SAL_13086 | Appetite-regulating hormone (Growth hormone secretagogue) (Growth hormone-releasing peptide) (Motilin-related peptide) (Protein M46) [Cleaved into: Ghrelin-27; Ghrelin-28 (Ghrelin); Obestatin] | NA | Ghrelin was measured in unstimulated total saliva using the same human-ghrelin-RIA kit, which is designed to test any biological fluid with sufficient levels of the peptide to be determined. | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | -2.0952381 | Downregulated | NA | Homo sapiens | 17244479 | 2007 | Q9UBU3 | Protein| SAL_14216 | Ig alpha-1 chain C region | NA | direct enzyme-linked immunosorbent assay | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 18976260 | 2009 | P01876 | Protein| SAL_14217 | IgG VH protein (Fragment) | NA | direct enzyme-linked immunosorbent assay | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 1 | NA | NA | NA | NA | Homo sapiens | 18976260 | 2009 | Q9Y298 | Protein| SAL_14218 | Rheumatoid factor G9 light chain (Fragment) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | A0N5G3 | Protein| SAL_14219 | Rheumatoid factor D5 light chain (Fragment) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | A0N5G5 | Protein| SAL_14220 | Rheumatoid factor RF-ET7 (Fragment) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | A2J1M4 | Protein| SAL_14221 | Rheumatoid factor RF-ET9 (Fragment) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | A2J1N6 | Protein| SAL_14222 | Inter-alpha (Globulin) inhibitor H2 (Inter-alpha (Globulin) inhibitor H2, isoform CRA_b) (cDNA FLJ75038, highly similar to Homo sapiens inter-alpha (globulin) inhibitor H2 (ITIH2), mRNA) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | 3.2 | Upregulated | NA | Homo sapiens | 19118452 | 2009 | A2RTY6 | Protein| SAL_14223 | Alpha-2-macroglobulin-like protein 1 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 9) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | A8K2U0 | Protein| SAL_14224 | Chloride intracellular channel protein 1 (Chloride channel ABP) (Nuclear chloride ion channel 27) (NCC27) (Regulatory nuclear chloride ion channel protein) (hRNCC) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O00299 | Protein| SAL_14225 | Sulfhydryl oxidase 1 (hQSOX) (EC 1.8.3.2) (Quiescin Q6) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O00391 | Protein| SAL_14226 | Beta-mannosidase (EC 3.2.1.25) (Lysosomal beta A mannosidase) (Mannanase) (Mannase) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O00462 | Protein| SAL_14227 | Syntenin-1 (Melanoma differentiation-associated protein 9) (MDA-9) (Pro-TGF-alpha cytoplasmic domain-interacting protein 18) (TACIP18) (Scaffold protein Pbp1) (Syndecan-binding protein 1) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O00560 | Protein| SAL_14228 | Ribonuclease T2 (EC 3.1.27.-) (Ribonuclease 6) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O00584 | Protein| SAL_14229 | Ficolin-1 (Collagen/fibrinogen domain-containing protein 1) (Ficolin-A) (Ficolin-alpha) (M-ficolin) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O00602 | Protein| SAL_14230 | Pyridoxal kinase (EC 2.7.1.35) (Pyridoxine kinase) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O00764 | Protein| SAL_14231 | Na(+)/H(+) exchange regulatory cofactor NHE-RF1 (NHERF-1) (Ezrin-radixin-moesin-binding phosphoprotein 50) (EBP50) (Regulatory cofactor of Na(+)/H(+) exchanger) (Sodium-hydrogen exchanger regulatory f | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O14745 | Protein| SAL_14232 | Tripeptidyl-peptidase 1 (TPP-1) (EC 3.4.14.9) (Cell growth-inhibiting gene 1 protein) (Lysosomal pepstatin-insensitive protease) (LPIC) (Tripeptidyl aminopeptidase) (Tripeptidyl-peptidase I) (TPP-I) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O14773 | Protein| SAL_14233 | Proteasome subunit alpha type-7 (EC 3.4.25.1) (Proteasome subunit RC6-1) (Proteasome subunit XAPC7) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O14818 | Protein| SAL_14234 | Actin-related protein 2/3 complex subunit 1B (Arp2/3 complex 41 kDa subunit) (p41-ARC) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O15143 | Protein| SAL_14235 | Actin-related protein 2/3 complex subunit 2 (Arp2/3 complex 34 kDa subunit) (p34-ARC) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O15144 | Protein| SAL_14236 | Actin-related protein 2/3 complex subunit 5 (Arp2/3 complex 16 kDa subunit) (p16-ARC) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | 6.1 | Upregulated | NA | Homo sapiens | 19118452 | 2009 | O15511 | Protein| SAL_14237 | Kallikrein-10 (EC 3.4.21.-) (Normal epithelial cell-specific 1) (Protease serine-like 1) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | -5 | Downregulated | NA | Homo sapiens | 19118452 | 2009 | O43240 | Protein| SAL_14238 | Kunitz-type protease inhibitor 1 (Hepatocyte growth factor activator inhibitor type 1) (HAI-1) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O43278 | Protein| SAL_14239 | Prominin-1 (Antigen AC133) (Prominin-like protein 1) (CD antigen CD133) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O43490 | Protein| SAL_14240 | CD5 antigen-like (Apoptosis inhibitor expressed by macrophages) (hAIM) (CT-2) (IgM-associated peptide) (SP-alpha) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O43866 | Protein| SAL_14241 | Aldo-keto reductase family 1 member B10 (EC 1.1.1.-) (ARL-1) (Aldose reductase-like) (Aldose reductase-related protein) (ARP) (hARP) (Small intestine reductase) (SI reductase) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | -3.3 | Downregulated | NA | Homo sapiens | 19118452 | 2009 | O60218 | Protein| SAL_14242 | Transmembrane protease serine 11D (EC 3.4.21.-) (Airway trypsin-like protease) [Cleaved into: Transmembrane protease serine 11D non-catalytic chain; Transmembrane protease serine 11D catalytic chain] | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | -2.1 | Downregulated | NA | Homo sapiens | 19118452 | 2009 | O60235 | Protein| SAL_14243 | Putative nucleoside diphosphate kinase (NDK) (NDP kinase) (EC 2.7.4.6) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O60361 | Protein| SAL_14244 | Periplakin (190 kDa paraneoplastic pemphigus antigen) (195 kDa cornified envelope precursor protein) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O60437 | Protein| SAL_14245 | Perilipin-3 (47 kDa mannose 6-phosphate receptor-binding protein) (47 kDa MPR-binding protein) (Cargo selection protein TIP47) (Mannose-6-phosphate receptor-binding protein 1) (Placental protein 17) ( | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O60664 | Protein| SAL_14246 | WD repeat-containing protein 1 (Actin-interacting protein 1) (AIP1) (NORI-1) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75083 | Protein| SAL_14247 | Core histone macro-H2A.1 (Histone macroH2A1) (mH2A1) (Histone H2A.y) (H2A/y) (Medulloblastoma antigen MU-MB-50.205) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75367 | Protein| SAL_14248 | SH3 domain-binding glutamic acid-rich-like protein | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75368 | Protein| SAL_14249 | Filamin-B (FLN-B) (ABP-278) (ABP-280 homolog) (Actin-binding-like protein) (Beta-filamin) (Filamin homolog 1) (Fh1) (Filamin-3) (Thyroid autoantigen) (Truncated actin-binding protein) (Truncated ABP) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75369 | Protein| SAL_14250 | Citrate synthase, mitochondrial (EC 2.3.3.1) (Citrate (Si)-synthase) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75390 | Protein| SAL_14251 | Vacuolar protein sorting-associated protein 26A (Vesicle protein sorting 26A) (hVPS26) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75436 | Protein| SAL_14252 | Mammaglobin-B (Lacryglobin) (Lipophilin-C) (Mammaglobin-2) (Secretoglobin family 2A member 1) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75556 | Protein| SAL_14253 | Peptidoglycan recognition protein 1 (Peptidoglycan recognition protein short) (PGRP-S) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75594 | Protein| SAL_14254 | Attractin (DPPT-L) (Mahogany homolog) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O75882 | Protein| SAL_14255 | Ly6/PLAUR domain-containing protein 3 (GPI-anchored metastasis-associated protein C4.4A homolog) (Matrigel-induced gene C4 protein) (MIG-C4) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | -2.3 | Downregulated | NA | Homo sapiens | 19118452 | 2009 | O95274 | Protein| SAL_14256 | 6-phosphogluconolactonase (6PGL) (EC 3.1.1.31) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O95336 | Protein| SAL_14257 | Apolipoprotein M (Apo-M) (ApoM) (Protein G3a) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O95445 | Protein| SAL_14258 | GDH/6PGL endoplasmic bifunctional protein [Includes: Glucose 1-dehydrogenase (EC 1.1.1.47) (Hexose-6-phosphate dehydrogenase); 6-phosphogluconolactonase (6PGL) (EC 3.1.1.31)] | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O95479 | Protein| SAL_14259 | Vascular non-inflammatory molecule 2 (Vanin-2) (EC 3.5.1.92) (Glycosylphosphatidyl inositol-anchored protein GPI-80) (Protein FOAP-4) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O95498 | Protein| SAL_14260 | N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 (DDAH-2) (Dimethylarginine dimethylaminohydrolase 2) (EC 3.5.3.18) (DDAHII) (Dimethylargininase-2) (Protein G6a) (S-phase protein) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | O95865 | Protein| SAL_14261 | L-lactate dehydrogenase A chain (LDH-A) (EC 1.1.1.27) (Cell proliferation-inducing gene 19 protein) (LDH muscle subunit) (LDH-M) (Renal carcinoma antigen NY-REN-59) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | P00338 | Protein| SAL_14262 | Glutamate dehydrogenase 1, mitochondrial (GDH 1) (EC 1.4.1.3) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | P00367 | Protein| SAL_14263 | Glutathione reductase, mitochondrial (GR) (GRase) (EC 1.8.1.7) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | P00390 | Protein| SAL_14264 | Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) (Superoxide dismutase 1) (hSod1) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | NA | NA | NA | Homo sapiens | 19118452 | 2009 | P00441 | Protein| SAL_14265 | Purine nucleoside phosphorylase (PNP) (EC 2.4.2.1) (Inosine phosphorylase) (Inosine-guanosine phosphorylase) | NA | Five saliva samples each from the control and DM groups were pooled separately and subjected to two-dimensional liquid chromatography (2-DLC) and LC-tandem mass spectrometry (LC-MS/MS) analysis | Whole Saliva | Metabolic Disorder | Diabetes Mellitus, Type 2 | NA | -2.1 | Downregulated | NA | Homo sapiens | 19118452 | 2009 | P00491 | Protein|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
